Dr. Mark Davis, discoverer of the first T-cell receptor genes and Stanford Professor, to advise the Company on immunological strategies for its novel cancer treatment platformLehi Utah, Jan. 07, 2026 ...

AbbVie’s deal team is having a busy week. Days after inking a $1.4 billion buyout, the drugmaker has put up the same again in biobucks to secure options on multispecific T-cell engagers from ...

Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of refractory or relapsed leukemia and hematologic malignancies, particularly over the past decade. Despite its ...

Cancer immunotherapy, especially using T cells, is showing a lot of promise in treating blood cancers. Bioengineered T cells, especially those equipped with chimeric antigen receptors (CAR-T cells), ...